Clara Rodríguez Fernández, Author at Labiotech.eu

About

Traveler, musician, food enthusiast and book worm. Always on the hunt for interesting facts and news.

Articles by Clara Rodríguez Fernández

Imperial College London incubator Hammersmith Hospital White City

News and Trends 6 Jun 2017

Imperial College Moves its Startup Incubator to a Bigger Facility in West London

Last Friday, the Duke of York opened Imperial’s newest facilities in the White City campus, where the university is relocating its startup incubator. Imperial College’s startup incubator, previously located at Imperial’s South Kensington campus, just got a significant upgrade with brand new facilities that opened last week in Imperial College’s White City campus. The new space, aptly renamed the White City […]

June 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Scenic Biotech Genetic Off Switch Cancer Rare Disease

News and Trends 5 Jun 2017

New Dutch Biotech Gets Funding to Find Genetic Off Switches

Scenic Biotech is applying a technology to identify first-in-class therapeutic targets that has secured it €6.5M in Series A. Scenic Biotech, founded in Amsterdam just this year, has raised €6.5M to exploit the potential of a technology to discover new types of disease-related genes with applications in cancer and rare genetic diseases. The company, created in […]

June 5, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 3 Jun 2017

The Microscopic World of Bacteria Comes to Life with Sculpture

Aimee Lax is a British sculptor that explores the bizarre world of microscopic life by making beautiful sculptures that magnify their tiny size. “There’s a whole world out there that we never see, but it’s all here, it’s all real,” says Aimee Lax. Her piece Bacteriophages was included in the permanent exhibition Invisible You – The […]

June 3, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Inthera Bioscience Protein Interactions Cancer

News and Trends 31 May 2017

Swiss Biotech raises €10M to Target Elusive Protein Interactions in Cancer

Inthera Bioscience has raised €9.6M in Series A to complete preclinical phase of its lead cancer program and expand its pipeline. Inthera Bioscience, located in Zurich, has closed a €9.6M (CHF 10.5M) Series A round led by Merck Ventures and backed by Novo Seeds and BioMedical Ventures, as well as a private investor. Members of Novo Seeds and […]

May 31, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 31 May 2017

Swiss Biotech raises €9M to Treat Sudden Hearing Loss in Phase III

Strekin has closed a Series C financing round that will fund the progression of its lead candidate for hearing loss to Phase III. Based in Basel, Strekin focuses on repurposing existing drugs by discovering new mechanisms of action. The company has now received €9.2M (CHF 10M) in Series C to fund the company’s activity until 2019 […]

May 31, 2017 - 1 minutemin - By Clara Rodríguez Fernández

trust me im an artist amsterdam bioart exhibition

News and Trends 27 May 2017

“Trust me, I’m an Artist” Explores the Ethics of Biotech in Amsterdam

The exhibition in Amsterdam showcases the works of ten bioartists questioning the huge complexity of ethics in the rapidly developing field of biotechnology. The Waag Society has brought together bioartists from all over Europe that explore topics like gene editing, antibiotics, human tissue culture, public health and personalized medicine. After a series of performances discussed […]

May 27, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

More News! 24 May 2017

Top Pharma eye British Tech to Predict Response to Checkpoint Inhibitors

Oxford BioDynamics will start the development of an epigenetic test to screen patients for a favorable response to anti-PD-L1 drugs. Oxford BioDynamics has announced an agreement with two of the top 10 global pharma to initiate the development of a blood-based test to predict the response to PD-L1 checkpoint inhibitors in patients with non-small cell […]

May 24, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Tolerogenixx cell therapy transplant High Tech Grunderfonds

More News! 24 May 2017

Seed Funding for a German Cell Therapy to Prevent Transplant Rejection

TolerogenixX has proved that it can get rid of immunosuppressants in organ transplants in Phase I and secured seed funding from High-Tech Gründerfonds. TolerogenixX is a startup from the Heidelberg University Hospital that develops personalized immunosuppression therapies. Its cell therapy technology has just passed Phase I, where it showed an “impressive efficacy” in preventing the rejection of […]

May 24, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

In Depth 24 May 2017

What Happens when the Immune System Attacks Life-Saving Drugs?

Immunogenicity has been largely disregarded despite its huge impact on the performance of biological drugs. What is it and how can we fight it? Immunogenicity can be a huge problem. Affecting especially protein-based drugs, this process consists in the development of anti-drug antibodies (ADAs) against a molecule that, in most cases, is saving the life […]

May 24, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 23 May 2017

Merck to Pay Ablynx €15M for Getting a Second Nanobody ready for the Clinic

Ablynx is receiving its first milestone payment from a deal with Merck for the development of first-in-class treatments for osteoarthritis. Belgium-based Ablynx develops nanobodies, molecules with the same properties as antibodies but with the advantage of being much smaller. This technology has attracted top pharma partners like AbbVie, MSD, Boehringer Ingelheim and Novartis. Now, the third […]

May 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

argenx llama antibody immuno oncology IPO

News and Trends 22 May 2017

UPDATE: Argenx’s IPO soars to over €100M to prove itself in Phase II

UPDATE (22/05/2017): Argenx has gone above and beyond to secure $115M (€103M) on the NASDAQ. Underwriters claimed all of the shares offered in over allotment, bringing the IPO to 50% more than the initial goal. Rather a lot for a company whose compound has yet to prove itself in Phase II. UPDATE (24/04/2017): Pricing terms have yet to be set, but the […]

May 22, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Interview 22 May 2017

Meet the New CEO of the Dutch Biotech Making a Cure for Blood Cancer

Arthur Lahr, CEO of Kiadis Pharma, explains the promising cell therapy the company is developing and discusses how the dutch biotech ecosystem has evolved. Arthur Lahr has been part of the Dutch biotech scene for over 15 years now. The former Chief Strategy Officer of Crucell, which was sold to J&J in 2011, is now […]

May 22, 2017 - 7 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Clara Rodríguez Fernández

About

Articles by Clara Rodríguez Fernández

Imperial College Moves its Startup Incubator to a Bigger Facility in West London

New Dutch Biotech Gets Funding to Find Genetic Off Switches

The Microscopic World of Bacteria Comes to Life with Sculpture

Swiss Biotech raises €10M to Target Elusive Protein Interactions in Cancer

Swiss Biotech raises €9M to Treat Sudden Hearing Loss in Phase III

“Trust me, I’m an Artist” Explores the Ethics of Biotech in Amsterdam

Top Pharma eye British Tech to Predict Response to Checkpoint Inhibitors

Seed Funding for a German Cell Therapy to Prevent Transplant Rejection

What Happens when the Immune System Attacks Life-Saving Drugs?

Merck to Pay Ablynx €15M for Getting a Second Nanobody ready for the Clinic

UPDATE: Argenx’s IPO soars to over €100M to prove itself in Phase II

Meet the New CEO of the Dutch Biotech Making a Cure for Blood Cancer

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Clara Rodríguez Fernández

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!